Preoperative serum levels of CEA and CA 19-9 and their prognostic significance in colorectal carcinoma
- PMID: 9329568
Preoperative serum levels of CEA and CA 19-9 and their prognostic significance in colorectal carcinoma
Abstract
The prognostic information provided by preoperative serum CEA, CA 19-9 antigen assays as compared with the classical prognostic factors (age, sex, tumor infiltration, tumor stage (Dukes') and R-classification) in 495 patients with colorectal carcinoma was analysed.
Patients and methods: Survival function estimates were calculated according to Kaplan-Meier. The patients were separated into two groups according to the preoperative marker levels. Fixing specificity at 100% for healthy people, cut off levels were calculated. Survival curve differences were assessed using the log-rank-test. Multivariate Cox's proportional hazard regression analysis was performed. The Mantel-Haenszel method was used to assess the survival rate of patients with colorectal carcinoma and high versus low levels of tumor-associated antigens according to tumor stages. The study was performed on the frozen sera (stored at -80 degrees C) of 495 patients with histologically proven colorectal carcinoma.
Results: The Dukes' stages (log-rank chi-square = 231.9; P < 0.0001) represent the best prognostic factor besides the preoperative values of CA 19-9 (log-rank chi-square = 162.5). CEA shows a log-rank chi-square of 71.4. Thus, CEA and CA 19-9 can be used to discriminate two groups of patients with significantly different survival times (P < 0.0001). The importance of different parameters in providing additional prognostic information was evaluated by multivariate analysis (Cox's model). Estimated relative risks of death adjusted for tumor stage were 5.5 for Dukes' stage A versus Dukes' stage B/C and Dukes' stage B/C versus Dukes' stage D, respectively and an increasing relative risk of 27.5 for Dukes' stage A versus Dukes' stage D (P < 0.001). The relative risk for preoperative CA 19-9 serum concentrations (> or = 60 U/mL versus < 60 U/mL) was 2.3 (P < 0.001) for preoperative CEA concentrations (> or = 4 ng/mL versus < 4 ng/mL) 1.4 (P < 0.07). For CEA the 2-years survival rates in the group of patients with preoperative serum concentrations > or = 4 ng/mL versus < 4 ng/mL and Dukes' stage D were 16% versus 38%, in Dukes' stage B/C 73% versus 91% and in Dukes' stage A 100% versus 98%. For CA 19-9 the 2-years survival rates in the group of patients with preoperative serum concentrations > or = 60 U/mL versus < 60 U/mL and Dukes' stage D were 10% versus 39%, in Dukes' stage B/C 58% versus 87%. In the group of patients with Dukes' stage A with serum levels > or = 60 U/mL a 2-year survival rate of 100% was found. In the corresponding group only one patient exists.
Conclusion: The postoperative Dukes' classification provides the best prognostic information besides the preoperative values of CA 19-9. The predictive information provided by the preoperative CA 19-9 serum level is additional to that obtained from the other factors investigated.
Similar articles
-
Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.Anticancer Res. 2000 Nov-Dec;20(6D):5195-8. Anticancer Res. 2000. PMID: 11326694
-
Prognostic value of preoperative serum levels of CEA, CA 19-9 and CA 72-4 in gastric carcinoma.Anticancer Res. 1997 Jul-Aug;17(4B):2903-6. Anticancer Res. 1997. PMID: 9329559
-
Prognostic significance of preoperative serum CA 19.9 assay in patients with colorectal carcinoma.Anticancer Res. 1994 Nov-Dec;14(6B):2819-25. Anticancer Res. 1994. PMID: 7872725 Clinical Trial.
-
[Antigens (CEA and CA 19-9) in diagnosis and prognosis colorectal cancer].Pol Merkur Lekarski. 2002 Jan;12(67):77-80. Pol Merkur Lekarski. 2002. PMID: 11957811 Review. Polish.
-
[Did the stage of diagnosis and the surgical management of colonic cancers change over the last ten years? Apropos of 303 patients].Ann Chir. 1994;48(7):591-5. Ann Chir. 1994. PMID: 7864533 Review. French.
Cited by
-
[Current status of the prognostic value of molecular markers in patients with colorectal cancer and the prediction of response to adjuvant therapy].Clin Transl Oncol. 2005 Apr;7(3):101-9. doi: 10.1007/BF02708742. Clin Transl Oncol. 2005. PMID: 15899217 Review. Spanish.
-
Comprehensive Evaluation of Relapse Risk (CERR) Score for Colorectal Liver Metastases: Development and Validation.Oncologist. 2020 Jul;25(7):e1031-e1041. doi: 10.1634/theoncologist.2019-0797. Epub 2020 Mar 17. Oncologist. 2020. PMID: 32181531 Free PMC article.
-
Anemia and long-term outcome in adjuvant and neoadjuvant radiochemotherapy of stage II and III rectal adenocarcinoma: the Freiburg experience (1989-2002).World J Gastroenterol. 2006 Mar 28;12(12):1849-58. doi: 10.3748/wjg.v12.i12.1849. World J Gastroenterol. 2006. PMID: 16609990 Free PMC article.
-
Detection of ANO1 mRNA in PBMCs is a promising method for GISTs diagnosis.Sci Rep. 2019 Jul 2;9(1):9525. doi: 10.1038/s41598-019-45941-2. Sci Rep. 2019. PMID: 31266974 Free PMC article.
-
Systemic inflammatory response associated with distant metastasis of T1 or T2 colorectal cancer.Dig Dis Sci. 2010 Nov;55(11):3181-7. doi: 10.1007/s10620-010-1159-8. Epub 2010 Mar 3. Dig Dis Sci. 2010. PMID: 20198429
MeSH terms
Substances
LinkOut - more resources
Medical